These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 19493917)

  • 1. "Who's winning the human race?"Cold war as pharmaceutical political strategy.
    Tobbell DA
    J Hist Med Allied Sci; 2009 Oct; 64(4):429-73. PubMed ID: 19493917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970.
    Tobbell DA
    Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug prices: real problem, wrong solution.
    Kennedy D
    Science; 2001 Jun; 292(5523):1797. PubMed ID: 11397914
    [No Abstract]   [Full Text] [Related]  

  • 4. Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008.
    Abraham J
    J Health Polit Policy Law; 2009 Dec; 34(6):931-77. PubMed ID: 20018987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 6. The Trading with the Enemy Act of 1917 and synthetic drugs: relieving scarcity, controlling prices, and establishing pre-market licensing controls.
    Cooper D
    Pharm Hist; 2005; 47(2):47-61. PubMed ID: 16447341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Globalization, pharmaceutical pricing, and South African health policy: managing confrontation with U.S. firms and politicians.
    Bond P
    Int J Health Serv; 1999; 29(4):765-92. PubMed ID: 10615573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 9. Coordinating on lower prices: pharmaceutical pricing under political pressure.
    Ellison SF; Wolfram C
    Rand J Econ; 2006; 37(2):324-40. PubMed ID: 17290546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 11. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 12. [The Brazilian pharmaceutical market and the North American war effort].
    Quintaneiro T
    Estud Hist; 2002; (29):141-64. PubMed ID: 18030707
    [No Abstract]   [Full Text] [Related]  

  • 13. Russian-American pharmaceutical relations, 1900-1945.
    Conroy MS
    Pharm Hist; 2004; 46(4):143-66. PubMed ID: 15991449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward allocative efficiency in the prescription drug industry.
    Guell RC; Fischbaum M
    Milbank Q; 1995; 73(2):213-30. PubMed ID: 7776946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent reform in the US: what's at stake for pharmaceutical innovation?
    Yancey A; Stewart CN
    Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical high profits: the value of R&D, or oligopolistic rents?
    Spitz J; Wickham M
    Am J Econ Sociol; 2012; 71(1):1-36. PubMed ID: 22319815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: business practices.
    Jones TM
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-54. PubMed ID: 19297719
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmaceutical industry and "New German Medicine" ("Neue Deutsche Heilkunde")].
    Meyer U
    Med Ges Gesch; 2004; 23():165-82. PubMed ID: 16025629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are rich nations up for drug reform?
    Check E
    Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
    [No Abstract]   [Full Text] [Related]  

  • 20. The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901-1902.
    Lilienfeld DE
    Perspect Biol Med; 2008; 51(2):188-98. PubMed ID: 18453724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.